-
PolyPid receives FDA support for D-PLEX100 drug application submission
-
PolyPid's (PYPD) DPLEX100 Demonstrates Positive Phase 3 Results - Citizens
-
PolyPid Ltd. (PYPD) Misses Q3 EPS by 4c
-
PolyPid completes israeli health ministry GMP inspection
-
PolyPid Ltd. (PYPD) Misses Q2 EPS by 21c
-
PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment
-
PolyPid Ltd. (PYPD) PT Lowered to $14 at Citizens JMP
-
PolyPid Ltd. (PYPD) PT Raised to $13 at H.C. Wainwright
-
PolyPid (PYPD) shares surge on successful D-PLEX100 trial results
-
PolyPid Ltd. (PYPD) to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
-
H.C. Wainwright Assumes PolyPid Ltd. (PYPD) at Buy
-
PolyPid Ltd. (PYPD) Tops Q1 EPS by 22c
-
H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD)
-
JMP Securities Biotechnology Overview
-
Rodman & Renshaw Starts PolyPid Ltd. (PYPD) at Buy
-
PolyPid Ltd. (PYPD) PT Lowered to $11 at H.C. Wainwright
-
PolyPid Ltd. (PYPD) Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
-
PolyPid Ltd. (PYPD) Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
-
Craig-Hallum Starts PolyPid Ltd. (PYPD) at Buy
-
PolyPid Ltd. (PYPD) Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal C
-
H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD)
-
PolyPid (PYPD) Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Inf
-
PolyPid Ltd. (PYPD) Files for 3.91M Share Offering by Selling Stockholders
-
PolyPid Ltd. (PYPD) Tops Q2 EPS by 5c

